Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.

Sci Rep · 2026 · PMC12913897 · PMID 41702946

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A retrospective study indicated that cyclosporine A (CsA) may reduce mortality in patients with severe COVID-19 52 .In a pilot randomized clinical trial, CsA showed a trend toward increasing the proportion of COVID-19 patients without interstitial lung disease at 3 months, including both those who did and did not require IMV 53 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.